Area privada5

Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.

Compartir:
CategoryParkinson

© 2022–2026 - UDIC - Unitat d'Investigació Clínica, SL · Soporte técnico